“Scholarship season” is now in full swing, time for an important reminder!
NHF’s Information service HANDI compiles an annual online list of post-secondary educational scholarships that are available to students living with bleeding disorders and…
When you have an ultra-rare bleeding disorder, it can be difficult to find the kind of specialized support you need. You need to talk to experts who understand the nuances of your disorder, and a community that knows what you…
When you live with hemophilia with an inhibitor, you and your family have questions and concerns that deserve special attention. NHF’s 2021 Virtual Inhibitor Education Series will provide just that – quality education and meaningful…
Cuando vive con hemofilia con un inhibidor, usted y su familia tienen preguntas e inquietudes que merecen una atención especial. La serie educativa sobre inhibidores virtuales 2021 de NHF proporcionará precisamente eso: educación de calidad y…
Important research using data from the My Life, Our Future (MLOF) Research Repository Phase One has been published in Frontiers in Medicine.
The article, “HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled…
The National Hemophilia Foundation (NHF) today, in conjunction with the American Kidney Fund (AKF), Arthritis Foundation, and American Autoimmune Related Diseases Association (AARDA), released findings from a new national online survey of patients…
Objective:
The completed pediatric phase 3 pathfinder 5 trial assessed the safety and efficacy of N8-GP (turoctocog alfa pegol, ESPEROCT®) use for routine prophylaxis and treatment of breakthrough bleeds in previously treated…
His project aims to directly address current limitations of hemophilia A gene and protein therapy by the identification and characterization of new hyperactive factor VIII variants based on his previous studies of hyperactive factor IX variants. He…
The recent American Society of Gene & Cell Therapy (ASGCT) Virtual Meeting featured updates from the phase III HOPE-B clinical trial of etranacogene dezaparvovec, an investigational gene therapy developed by uniQure for patients with severe…